• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Psilocybin: The New Holy Grai­l for the Rapid Relief of Major ­Depression?

Psilocybin: The New Holy Grai­l for the Rapid Relief of Major ­Depression?

July 14, 2021
Paul Barkopoulos, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Paul Barkopoulos, MD. Dr. Barkopoulos has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Davis AK et al, JAMA ­Psychiatry 2020:e203285

Intravenous ketamine and intranasal esketamine (Spravato) offer hope in the search for a rapidly acting antidepressant. However, concerns regarding addiction, safety, and effect durability have prompted searches for alternative rapid-acting treatments. Psilocybin is a hallucinogen originally derived from “magic mushrooms” that, like ketamine, is a recreational drug with potential antidepressant effects. Recently, researchers published the first controlled study to explore its efficacy for depression.

Participants diagnosed with moderate to severe depression, and not taking antidepressants, were randomly assigned to a treatment group (n = 14) or a delayed-treatment/waiting-list control group (n = 13). During the initial 8 weeks, the immediate-treatment group received 3 weeks of preparatory therapy followed by two day-long sessions in which they received a lower dose of psilocybin (20 mg/70 kg) in session 1 and a higher dose (30 mg/70 kg) in session 2. During the psilocybin sessions, they received supportive therapy and were encouraged to focus their attention inward as they listened to music. Patients who were randomized to the delayed group were also provided the active 8-week psilocybin protocol after first serving as a no-treatment control for the immediate group.

How well did psilocybin work? In those first 8 weeks, the immediate group responded rapidly and significantly compared to the control group. Subjects in the control group experienced no improvement while waiting, but once treated, they responded as robustly as the immediate group on all measures. At 1 week and 4 weeks after the last drug session, 67% and 71% of pooled treated subjects, respectively, demonstrated a clinically significant response (greater than 50% drop in GRID HAM-D scores). At those same 1- and 4-week measurement points, 58% and 54% of treated subjects, respectively, experienced remission (GRID HAM-D score < 7).

Psilocybin was well tolerated. The main side effects included vague emotional symptoms (fear, sadness) and physical symptoms (such as a trembling sensation and mild, transient headaches).

CHPR’s Take
Psilocybin appears to rapidly and significantly reduce depressive symptoms. Unlike ketamine, psilocybin is not addictive, and its antidepressant efficacy seems to last longer (weeks vs days for ketamine). We’ll need larger studies to have more confidence in its efficacy.
Hospital Psychiatry
KEYWORDS depression ketamine mood pharmacotherapy psilocybin rapid-acting
    Paul Barkopoulos, MD.

    QT Intervals in Psychiatric Practice

    More from this author
    www.thecarlatreport.com
    Issue Date: July 14, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Metabolic Side Effects, CHPR, July/August/September 2021
    Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain
    Weight Gain and Metabolic Side Effects
    Sex-Based Treatment of Schizophrenia
    New Combination Treatment Mitigates Antipsychotic-Induced Weight Gain
    Anti-NMDA Receptor Encephalitis or New-Onset Psychosis?
    Psilocybin: The New Holy Grai­l for the Rapid Relief of Major ­Depression?
    DOWNLOAD NOW
    Featured Book
    • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

      Treating Alcohol Use Disorder: A Fact Book (2023)

      All the tools and information needed to assess and treat your patients who are struggling with...
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto104192710.jpg
      Hospital Psychiatry

      Management of Depression and Neurocognitive Impairment in Patients With HIV

      Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.